US EPA

3862880 

Journal Article 

Anti-allergic and Profilaggrin (ProFLG)-mRNA expression modulatory effects of sacran 

Ngatu, NR; Motoyama, K; Nishimura, Y; Okajima, MK; Hirota, R; Higashi, T; Lee, S; Arima, H; Ikeda, M; Nojima, S; Kaneko, T 

2017 

Yes 

International Journal of Biological Macromolecules
ISSN: 0141-8130
EISSN: 1879-0003 

105 

Pt 2 

1532-1538 

English 

28522399 

10.1016/j.ijbiomac.2017.05.049 

WOS:000415779800022 

Atopic dermatitis (AD) is a skin disorder characterized by filaggrin (FLG) defect. We evaluated sacran's effects on dust-mite extracts (DME)-induced AD-like disease and also its effect on profilaggrin (proFLG) in a murine model of 2,4-dinitroflurobenze (DNFB)-induced contact hypersensitivity. In the murine AD-like disease model, allergic NC/Nga mice (N=60) were randomly divided into five treatment groups of 12 animals each: 0.2% and 1%sacran; 0.1% Tacrolimus; Vaseline and buffer-treated controls. Blood samples were drawn and serum levels of representative Th-1, Th-2 and also Th-17 (IL-17A) cytokines were assayed by Cytometric Bead Array (CBA). In the contact hypersensitivity model, diseased NC/Nga mice (N=20) were divided into four groups of five mice each [0.05%sacran, 0.05% chondroitin sulfate (CS), 0.5% prednisolone (PD), non-treated control group] and were treated for 14days. Skin biopsies were performed for the measurement of proFLG-mRNA by real-time PCR. Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-γ, TNF-α, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls). Additionally, a marked increase of proFLG-mRNA expression was observed in 0.05%sacran group (vs. control 0.05% CS and 0.5% PD groups). Thus, Sacran might be useful as a natural skin barrier enhancer and anti-allergic agent. 

Atopic dermatitis; Profilaggrin